A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of subcutaneous NT100 vs placebo following in vitro fertilization (IVF) in women with a history of repeated IVF failures.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nora Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Pre-menopausal female 21-38 years of age at screening

• History of repeated IVF failures despite transfer of good-quality embryos, defined as follows:

• ...1) 3 or more IVF cycles involving transfer of at least two good-quality cleavage-stage embryos or at least one good-quality blastocyst (2010 SART (Society for Assisted Reproductive Technologies) grading criteria)that resulted in one of the following outcomes:

• * .....a) no pregnancy

• * .....b) biochemical pregnancy

• * .....c) spontaneous abortion of an intrauterine clinical pregnancy before or equal to completed Week 8 of gestation

• ...2) At least two of the eligible IVF failures must have involved transfer of fresh embryos

• ...3) At least two of the eligible IVF failures must have involved retrieval of at least 5 oocytes

• ...4) No live birth, abortion later than Week 8 of gestation, or stillbirth may have occurred since the first of these IVF failures

• Body mass index (BMI) of 19-38 kg per m2 at screening

• TSH (thyroid-stimulating hormone) less than or equal to 4.0 mIU/L(milli-International units per Liter) for subjects with no history of hypothyroidism, or TSH less than or equal to 2.5 mIU/L for subjects with a history of hypothyroidism, at screening

Exclusion Criteria:

• Prior diagnosis of moderate or severe ovarian hyperstimulation syndrome (OHSS)

• Clinically confirmed polycystic ovary syndrome (PCOS)

• History of a major congenital anomaly in the subject, her current male partner, or first degree relative of either the subject or her current male partner

• Known karyotype abnormalities in either the subject or her current male partner / sperm donor

• Any prior pregnancy terminated for a fetal medical condition

• History of severe (stage IV) endometriosis

• Current or past systemic autoimmune disease

• Any uncontrolled clinically significant medical condition (e.g. asthma, Type II diabetes, infection)